| Market Crux Exclusive Profile For Monday 3/17/2025 Has Been Announced!
Galmed Pharmaceuticals (Nasdaq: GLMD) Is Our Next Potential Breakout Idea For Tomorrow—Here’s Why…
According To Technical Indicators, (GLMD) Appears To Be Entering An Oversold Territory — Which Could Suggest The Potential For A Trend Reversal.
There’s Less Than 1.65M Shares Listed In The Public Float For (GLMD) — Which Could Lead To The Potential For Significant Swings If Demand Begins To Shift.
Then—Just A Few Days Ago, On Friday 3/14/2025, Maxim Group Published A Report With A $12 Target On (GLMD) — Which Suggests An Upside Potential Of Over 597% From Its $1.72 Close.
Keep Reading To See Why Galmed Pharmaceuticals (NASDAQ: GLMD) Is Topping Our Watchlist For Early This Morning…
March 17, 2025
Dear Reader,
Did you pull this up?
Galmed Pharmaceuticals (Nasdaq: GLMD) reached $2.40 this morning, marking an approximate 39% move from Friday’s $1.72 close.
This highlights the potential for technical momentum as (GLMD) surpassed several key moving averages including: 5-Day: 1.7805 20-Day: 2.1752
With its 50-Day moving average at 2.5733, 100-Day at 2.8796, and 200-Day at 3.5727, we’re keeping a very close eye on (GLMD) right now.
Keep reading to see why (GLMD) is topping our watchlist early this morning.
If history is any indication, this could be worth watching.
Here’s why…
The last time we covered (GLMD), it skyrocketed approximately 182% in less than 24 hours.
And with our previous two Sunday Night Profiles combining for 175% (approx.) moves, we’re keeping a close eye on (GLMD) heading into tomorrow morning’s session.
You see, biotech and pharma are some of the most exciting industries, where a single breakthrough can turn an under-the-radar company into a major market player overnight.
Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on liver, metabolic, and fibro-inflammatory diseases.
The company is advancing Aramchol Meglumine, a potential treatment for Primary Sclerosing Cholangitis (PSC) and other fibrotic conditions.
Aramchol, in Phase 3 clinical development, has already demonstrated significant fibrosis improvement in patients with NASH and fibrosis, as published in Hepatology.
As the most advanced SCD-1 downregulator in clinical trials, Aramchol continues to show potential in multiple therapeutic areas. Learn more here.
On Friday, 3/14/2025, Maxim Group published a report which listed Galmed Pharmaceuticals (Nasdaq: GLMD) with a $12 target, which suggests an upside potential of over 597% from its $1.72 close.
Galmed Pharmaceuticals (Nasdaq: GLMD) Is Topping Our Early Watchlist This Morning—And Here’s Why…
1. Technical Signals: According to technical indicators found on Barchart, (GLMD) appears to be entering an oversold territory, which could suggest the potential for a trend reversal.
2. Razor Float: There’s less than 1.65M shares listed in the public float for (GLMD). This limited float could lead to the potential for significant swings if demand begins to shift.
3. Recent Analyst Coverage: Just a few days, on Friday 3/14/2025, Maxim Group published a report with a $12 target on (GLMD), which suggests an upside potential of over 597% from its $1.72 close.
Now’s The Time to Consider Adding Galmed Pharmaceuticals (Nasdaq: GLMD) to Your Radar This Morning—While It’s Still Early…
We’ve seen it before—when a profile like this starts catching momentum, things can move fast.
Consider taking a look at (GLMD) while it’s still early.
(GLMD) is at the top of our watchlist early this morning.
Now remember— the last time we covered (GLMD), it moved approximately 182% in less than 24 hours. And please keep an out for my next update—it could be out to you any minute. | 
ليست هناك تعليقات:
إرسال تعليق